Real-world outcomes in patients with primary biliary cholangitis who initiated elafibranor treatment with baseline alkaline phosphatase levels between 1× to 1.67× the upper limit of normal

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Real-world outcomes in patients with primary biliary cholangitis who initiated elafibranor treatment with baseline alkaline phosphatase levels between 1× to 1.67× the upper limit of normal

	EASL 2026May 26-30 Barcelona Cynthia Levy,1,2